Yuk Inn H Y, Olsen Matthew M, Geyer Scott, Forestell Sean P
Onyx Pharmaceuticals, Inc., Richmond, California, USA.
Biotechnol Bioeng. 2004 Jun 20;86(6):637-42. doi: 10.1002/bit.20158.
This study demonstrates the novel use of the HeLaS3 human tumor cell line for propagating ONYX-411, a recombinant oncolytic adenoviral vector. HeLaS3 cells enabled high levels of vector production without the risk of generating vector recombinants, which is possible with HEK293 cells. The development of a high-cell-density perfusion process using ATF technology yielded production levels as high as 6 x 10(11) vp/mL, which was approximately sevenfold greater than the titers achieved in fed-batch bioreactors. Several experiments were performed at the bench (15 L) and pilot (70 L) scales to demonstrate the robust and scalable nature of this industrially relevant technology.
本研究展示了HeLaS3人肿瘤细胞系在繁殖ONYX - 411(一种重组溶瘤腺病毒载体)方面的新用途。HeLaS3细胞能够实现高水平的载体生产,且不存在产生载体重组体的风险,而这在HEK293细胞中是可能的。使用自动切向流过滤(ATF)技术开发的高细胞密度灌注工艺,其生产水平高达6×10¹¹ vp/mL,比补料分批生物反应器中获得的滴度高出约7倍。在实验室规模(15 L)和中试规模(70 L)进行了多项实验,以证明这项与工业相关技术的稳健性和可扩展性。